Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Victoria T Brown"'
Autor:
Robert J. Ignoffo, Amy Hatfield Seung, Grazyna Rieband, Victoria T Brown, Angela Urmanski, Shannon Hough, Alison Palumbo, Katherine K. Knapp, Thu Oanh Dang
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:5-13
Objective The purpose of this study was to identify trends in oncology care that allow one to forecast workforce supply and demand, the training and skills needed by the oncology pharmacist for the likely future of oncology care. Methods Interviews w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03c85697422232ce8307641a9be19a2d
https://doi.org/10.1177/1078155220907674
https://doi.org/10.1177/1078155220907674
Autor:
Christopher R Manz, Justin T. Puckett, Victoria T Brown, Pengxiang Li, Jordan Jahnke, Jalpa A. Doshi, Swathi Raman, Melea A Ward
Publikováno v:
Journal of managed carespecialty pharmacy. 27(10)
BACKGROUND: Few studies have examined oral anticancer treatment utilization patterns among Medicare beneficiaries. OBJECTIVE: To assess treatment utilization patterns of newly initiated oral anticancer agents across national samples of Medicare benef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fe29527ced1164558b67104a55a1688
https://pubmed.ncbi.nlm.nih.gov/34595957
https://pubmed.ncbi.nlm.nih.gov/34595957
Autor:
Molly Wascher, Cathy L. Walker, Janet Mighty, Meghan Tolan, Victoria T Brown, Daniel M. Ashby, Anne DeLisa, Todd W. Nesbit, Michelle A. Rudek
Publikováno v:
Am J Health Syst Pharm
Purpose The development, structure, and implementation of an innovative residency program designed to help meet a growing need for pharmacists with specialized expertise in investigational drug use and clinical research are described. Summary Clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ad5a1652fa5f3809c9e372522971b91
https://doi.org/10.1093/ajhp/zxz175
https://doi.org/10.1093/ajhp/zxz175
Publikováno v:
Journal of the National Comprehensive Cancer Network. 17:CLO19-028
Background: Anti-PD1/PD-L1 therapy is standard-of-care for patients with a variety of advanced malignancies. Although clinical trials report a lower incidence of grade 3-4 toxicities than observed with cytotoxic agents, it is imperative that clinicia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b22a8c82f22231d39fa02bf0b5cc47ef
https://doi.org/10.6004/jnccn.2018.7188
https://doi.org/10.6004/jnccn.2018.7188
Publikováno v:
Cancer investigation. 39(10)
Purpose We assessed real-world spectrum and patterns of irAEs for patients treated with anti-PD(L)1 ICIs. Methods irAEs were defined using medical and pharmacy claims for patients enrolled in a Medicare Advantage Prescription Drug plan who initiated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::440a4e0e34ff50d7804247b5a08124a2
https://pubmed.ncbi.nlm.nih.gov/33829943
https://pubmed.ncbi.nlm.nih.gov/33829943
Publikováno v:
American Journal of Health-System Pharmacy. 74:1938-1942
Over the past decade, FDA has approved several targeted therapies for various cancers. The development of targeted agents has resulted in an increase in the cost of anticancer drugs.[1][1] According to the QuintilesIMS Institute for Healthcare Inform
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d7c54d656954999c3ef1dd112adce23
https://doi.org/10.2146/ajhp170029
https://doi.org/10.2146/ajhp170029
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 25(2)
Purpose Patients with head and neck cancer are at risk for disease- and treatment-related toxicities that may be severe enough to require hospitalization. The risk factors associated with hospitalization in these patients are not well defined. Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2abdf977a3e2e62808476c7fa8071f15
https://pubmed.ncbi.nlm.nih.gov/29050538
https://pubmed.ncbi.nlm.nih.gov/29050538
Autor:
Amy Wiglesworth Bryk, Lauren D McBride, Jamie L. Elsner, Macey Williams, Victoria T Brown, Dina J. Benani, Cathy Cao
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S336
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efedbbd12d3f47f712248744ecfbba86
https://doi.org/10.1016/j.bbmt.2017.12.283
https://doi.org/10.1016/j.bbmt.2017.12.283
Autor:
Amy Wiglesworth Bryk, Allison R Butts, Victoria T Brown, Javier Bolaños-Meade, Lauren D McBride
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 22(2)
Objective The primary objective was to analyze the initial tacrolimus concentrations achieved in allogeneic hematopoietic stem cell transplantation patients using the institutional dosing strategy of 1 mg IV daily initiated on day +5. The secondary o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a686a9c7fb09d664e0af4315402e10a4
https://pubmed.ncbi.nlm.nih.gov/25802301
https://pubmed.ncbi.nlm.nih.gov/25802301
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 21(1)
Over the last decade, numerous drug therapies have emerged for the treatment of multiple myeloma including immunomodulating agents namely thalidomide, lenalidomide, and pomalidomide and proteasome inhibitors namely bortezomib and carfilzomib. These a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3be06355dda5d736fa534a5a801ef8fb
https://pubmed.ncbi.nlm.nih.gov/24395544
https://pubmed.ncbi.nlm.nih.gov/24395544